That said, CASP3 activation has been mechanistically associated with immunoevasion through a number of distinct mechanisms in various preclinical tumor models (including MC38 CRCs), and whether CASP3 is indeed responsible for sIL18 generation in vivo remains to be formally established. The gene discussed is CASP3; the disease is neoplasm.